Patents by Inventor Jorg Czech

Jorg Czech has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fusion proteins for prodrug activation
    Patent number: 7273727
    Abstract: The invention relates to compounds which contain an antigen binding region which is bound to at least one enzyme which is able to metabolize a compound (prodrug) which has little or no cytotoxicity to a cytotoxic compound (drug), where the antigen binding region is composed of a single polypeptide chain. It is advantageous for covalently bonded carbohydrates to be present on the polypeptide chain.
    Type: Grant
    Filed: May 23, 2005
    Date of Patent: September 25, 2007
    Assignee: Behrinwerke Aktiengesellschaft
    Inventors: Mathias Gehrmann, Gerhard Seeman, Klaus Bosslet, Jorg Czech
  • Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
    Patent number: 7241595
    Abstract: The present invention relates to glycosyl-etoposide prodrugs, a process for the preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates for treating cancers.
    Type: Grant
    Filed: April 24, 2002
    Date of Patent: July 10, 2007
    Assignee: sanofi-aventis Pharma Deutschland GmbH
    Inventors: Cenek Kolar, Jörg Czech, Klaus Bosslet, Gerhard Seemann, Hans-Harald Sedlacek
  • Fusion proteins for prodrug activation
    Publication number: 20060292139
    Abstract: The invention relates to compounds which contain an antigen binding region which is bound to at least one enzyme which is able to metabolize a compound (prodrug) which has little or no cytotoxicity to a cytotoxic compound (drug), where the antigen binding region is composed of a single polypeptide chain. It is advantageous for covalently bonded carbohydrates to be present on the polypeptide chain.
    Type: Application
    Filed: May 23, 2005
    Publication date: December 28, 2006
    Applicant: Aventis Pharma Deutschland
    Inventors: Mathias Gehrmann, Gerhard Seemann, Klaus Bosslet, Jorg Czech
  • Fusion proteins for prodrug activation
    Patent number: 7060495
    Abstract: The invention relates to compounds which contain an antigen binding region which is bound to at least one enzyme which is able to metabolize a compound (prodrug) which has little or no cytotoxicity to a cytotoxic compound (drug), where the antigen binding region is composed of a single polypeptide chain. It is advantageous for covalently bonded carbohydrates to be present on the polypeptide chain.
    Type: Grant
    Filed: December 12, 1997
    Date of Patent: June 13, 2006
    Assignee: Behrinwerke Aktienegesellschaft
    Inventors: Mathias Gehrmann, Gerhard Seemann, Klaus Bosslet, Jörg Czech
  • Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
    Patent number: 6610299
    Abstract: The present invention relates to glycosyl-etoposide prodrugs, a process for the preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates for treating cancers.
    Type: Grant
    Filed: October 19, 1994
    Date of Patent: August 26, 2003
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Cenek Kolar, Jörg Czech, Klaus Bosslet, Gerhard Seemann, Hans-Harald Sedlacek, Dieter Hoffmann
  • Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
    Publication number: 20030064482
    Abstract: The present invention relates to glycosyl-etoposide prodrugs, a process for the preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates for treating cancers.
    Type: Application
    Filed: April 24, 2002
    Publication date: April 3, 2003
    Applicant: Hoechst Aktiengesellschaft
    Inventors: Cenek Kolar, Jorg Czech, Klaus Bosslet, Gerhard Seemann, Hans-Harald Sedlacek, Dieter Hoffman
  • Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
    Patent number: 6475486
    Abstract: The present invention relates to glycosyl-etoposide prodrugs, a process for the preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates for treating cancers.
    Type: Grant
    Filed: June 30, 1999
    Date of Patent: November 5, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Cenek Kolar, Jörg Czech, Klaus Bosslet, Gerhard Seemann, Hans-Harald Sedlacek, Dieter Hoffman
  • FUSION PROTEINS FOR PRODRUG ACTIVATION
    Publication number: 20020068329
    Abstract: The invention relates to compounds which contain an antigen binding region which is bound to at least one enzyme which is able to metabolize a compound (prodrug) which has little or no cytotoxicity to a cytotoxic compound (drug), where the antigen binding region is composed of a single polypeptide chain. It is advantageous for covalently bonded carbohydrates to be present on the polypeptide chain.
    Type: Application
    Filed: December 12, 1997
    Publication date: June 6, 2002
    Applicant: Behringwerke Aktiengesellschaft
    Inventors: MATHIAS GEHRMANN, GERHARD SEEMANN, KLAUS BOSSLET, JORG CZECH
  • Prodrugs, their preparation and use as pharmaceuticals
    Patent number: 6146658
    Abstract: Glycosyl-spacer-drugs compounds (prodrugs), their preparation and their use as pharmaceuticals are described.
    Type: Grant
    Filed: May 20, 1997
    Date of Patent: November 14, 2000
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Klaus Bosslet, Jorg Czech, Dieter Hoffmann, Cenek Kolar, Fran.cedilla.ois Tillequin, Jean-Claude Florent, Michel Azoulay, Claude Monneret, Jean-Claude Jacquesy, Jean-Pierre Gesson, Michel Koch
  • Preparation having increased in vivo tolerability
    Patent number: 6020315
    Abstract: A preparation having increased in vivo tolerability comprising a glycosyl-Y[--C(.dbd.Y)--X--].sub.p --W(R).sub.n --X--C(.dbd.Y)-active compound, sugar or sugar alcohol and, optionally divalent ions, and a pharmaceutically tolerable carrier.
    Type: Grant
    Filed: May 13, 1998
    Date of Patent: February 1, 2000
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Klaus Bosslet, Jorg Czech, Manfred Gerken, Rainer Straub, Matthias Blumrich
  • Use of isoxazole and crotonamide derivatives for the treatment of carcinomatous disorders
    Patent number: 6020372
    Abstract: The compound of the formula I or II ##STR1## is suitable for the production of a pharmaceutical for the treatment of carcinomatous disorders, where R.sup.1 is (C.sub.3 -C.sub.5)-cycloalkyl, (C.sub.2 -C.sub.6)-alkenyl or (C.sub.2 -C.sub.6)-alkynyl, R.sup.2 is CF.sub.3, OCF.sub.3, SCF.sub.3, OH, NO.sub.2, halogen, benzyl, phenyl, CN or O-phenyl, R.sup.3 is (C.sub.1 -C.sub.4)-alkyl, halogen or a hydrogen atom and X is a --CH group or a nitrogen atom.
    Type: Grant
    Filed: November 13, 1998
    Date of Patent: February 1, 2000
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Wilfried Schwab, Jorg Czech, Klaus Boslett
  • Prodrugs their preparation and use as pharmaceuticals
    Patent number: 5955100
    Abstract: Glycosyl-spacer-drugs compounds (prodrugs), their preparation and their use as pharmaceuticals are described.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: September 21, 1999
    Assignees: Behringwerke Aktiengesellschaft, Laboratories Hoechst S/A
    Inventors: Klaus Bosslet, Jorg Czech, Dieter Hoffmann, Cenek Kolar, Fran.cedilla.ois Tillequin, Jean-Claude Florent, Michel Azoulay, Claude Monneret, Jean-Claude Jacquesy, Jean-Pierre Gesson, Michel Koch
  • Prodrugs for the therapy of tumors and inflammatory disorders
    Patent number: 5935995
    Abstract: Compounds of the formula Iglycosyl-Y?--C(.dbd.Y)--X--!.sub.p --W(R).sub.n --Z--C(.dbd.Y)-active compound (I)are described which are suitable for the treatment of carcinomatous diseases, autoimmune diseases and chronic inflammatory diseases such as rheumatoid arthritis.
    Type: Grant
    Filed: March 11, 1997
    Date of Patent: August 10, 1999
    Assignee: Heochst Aktiengesellschaft
    Inventors: Klaus Bosslet, Jorg Czech, Manfred Gerken, Rainer Straub, Claude Monneret, Jean-Claude Florent, Frederic Schmidt
  • Use of isoxazole and crotonamide derivatives for the treatment of carcinomatous disorders
    Patent number: 5886033
    Abstract: The use of isoxazole and crotonamide derivatives for the treatment of carcinomatous disordersThe compound of the formula I or II ##STR1## is suitable for the production of a pharmaceutical for the treatment of carcinomatous disorders, where R.sup.1 is (C.sub.3 -C.sub.5)-cycloalkyl, (C.sub.2 -C.sub.6)-alkenyl or (C.sub.2 -C.sub.6)-alkynyl, R.sup.2 is CF.sub.3, OCF.sub.3, SCF.sub.3, OH, NO.sub.2, halogen, benzyl, phenyl, CN or O-phenyl, R.sup.3 is (C.sub.1 -C.sub.4)-alkyl, halogen or a hydrogen atom and X is a --CH group or a nitrogen atom.
    Type: Grant
    Filed: October 16, 1996
    Date of Patent: March 23, 1999
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Wilfried Schwab, Jorg Czech, Klaus Boslett
  • Pro-prodrugs, their production and use
    Patent number: 5877158
    Abstract: Substrate-spacer-prodrug compounds (pro-prodrugs) suited for site specific delivery of drugs, a process of preparing them and their use are described.
    Type: Grant
    Filed: September 20, 1994
    Date of Patent: March 2, 1999
    Assignees: Behringwerke Aktiengesellschaft, Laboratoires Hoechst S/A
    Inventors: Klaus Bosslet, Jorg Czech, Dieter Hoffmann, Fran.cedilla.ois Tillequin, Jean-Claude Florent, Michel Azoulay, Claude Monneret, Jean-Claude Jacquesy, Jean-Pierre Gesson, Michel Koch
  • Inhibitors of .beta.-glucuronidase and their use in the treatment of carcinamatosis and inflammation
    Patent number: 5817800
    Abstract: Compounds of the formulae I and II ##STR1## are suitable for the suppression of tumor growth and of tumor metastasis.
    Type: Grant
    Filed: August 1, 1997
    Date of Patent: October 6, 1998
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Klaus Bosslet, Jorg Czech, Andrea Vasella, Roland Hoos
  • Combination of necrosis-inducing substances with substances which are activated by necroses for the selective therapy of tumors and inflammatory disorders
    Patent number: 5710134
    Abstract: The invention relates to a combination of substances (component I) inducing necrosis in tumors or inflamed tissue with other nontoxic substances ("prodrugs", component II). The enzymes set free by necrotic processes then cleave the nontoxic "prodrug" into the toxic "drug", which leads to massive tumor cell death and/or remission of inflammation.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: January 20, 1998
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Klaus Bosslet, Jorg Czech, Dieter Hoffmann
  • Substituted phenols and their use for the treatment of disorders caused by cell proliferation
    Patent number: 5519018
    Abstract: Substituted phenols of the formula I ##STR1## processes for their preparation and compositions containing substituted phenols of the formulae I and II ##STR2## for the treatment of disorders caused by cell proliferation, such as psoriasis, tumor disorders and immunological disorders, are described.
    Type: Grant
    Filed: May 1, 1995
    Date of Patent: May 21, 1996
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Rudolf Matusch, Manfred Hunz, Jorg Czech, Hans-Harald Sedlacek
  • Use of derivatives of 9,10-dihydrophenanthrene for the preparation of an anti-tumor medicament
    Patent number: 5189065
    Abstract: The use of products of formula (I) is described, wherein X and Y represent hydrogen, hydroxy or alkoxy; and R.sub.1 and R.sub.2 represent H, alkyl, alkenyl or alkynyl, arylalkyl, acyl or R.sub.1 and R.sub.2 together with nitrogen form a heterocycle for preparing an antitumoral drug.
    Type: Grant
    Filed: October 17, 1991
    Date of Patent: February 23, 1993
    Assignee: Roussel Uclaf
    Inventors: Jorg Czech, Hans H. Sedlacek, Lucien Nedelec, Jacques Guillaume, Christian Marchandeau